Is Alzheimer's disease a systemic disease?

Biochimica et Biophysica Acta - Molecular Basis of Disease

Volumn 1842, Issue 9, 2014, Pages 1340-1349

  Morris, Jill K ^a   Honea, Robyn A ^a   Vidoni, Eric D ^a   Swerdlow, Russell H ^a   Burns, Jeffrey M ^a  

^a UNIVERSITY OF KANSAS   (United States)

Author keywords

Alzheimer's disease; Exercise; Metabolism; Mitochondria; Physical activity

Indexed keywords

BRAIN DERIVED NEUROTROPHIC FACTOR; BRAIN NATRIURETIC PEPTIDE; C REACTIVE PROTEIN; CYTOKINE; MITOCHONDRIAL DNA; REACTIVE OXYGEN METABOLITE;

ADAPTATION; ALZHEIMER DISEASE; AUTONOMIC NERVOUS SYSTEM; BEHAVIOR CHANGE; BIOENERGY; BLOOD BRAIN BARRIER; BODY COMPOSITION; BODY MASS; BONE DENSITY; BRAIN SIZE; COGNITION; DEFAULT MODE NETWORK; DEMENTIA; DIABETES MELLITUS; ENERGY METABOLISM; ENVIRONMENTAL FACTOR; EXTRACHROMOSOMAL INHERITANCE; FAMILY HISTORY; GENETIC RISK; HEREDITY; HIPPOCAMPUS; HUMAN; HUMAN GENETICS; HYPOTHALAMUS; IMPAIRED GLUCOSE TOLERANCE; INSULIN RESISTANCE; LIPID METABOLISM; LONG TERM POTENTIATION; MITOCHONDRION; MULTIINFARCT DEMENTIA; NERVOUS SYSTEM DEVELOPMENT; NEUROPATHOLOGY; NEUROTRANSMISSION; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; OXIDATIVE STRESS; PHYSICAL ACTIVITY; PRIORITY JOURNAL; RESISTANCE TRAINING; REVIEW; SYSTEMIC DISEASE; WHITE MATTER LESION; BRAIN DYSFUNCTION; DISORDERS OF MITOCHONDRIAL FUNCTIONS; INFLAMMATION;

ALZHEIMER'S DISEASE; EXERCISE; METABOLISM; MITOCHONDRIA; PHYSICAL ACTIVITY;

ALZHEIMER DISEASE; HUMANS; NEURODEGENERATIVE DISEASES; RISK FACTORS;

EID: 84903441756     PISSN: 09254439     EISSN: 1879260X     Source Type: Journal    
DOI: 10.1016/j.bbadis.2014.04.012     Document Type: Review

References (224)

1. Thies W., Bleiler L., A.Alzheimer's 2013 Alzheimer's disease facts and figures. Alzheimers Dement. 2013, 9(2):208-245.
2. Agosta F., Pievani M., Sala S., et al. White matter damage in Alzheimer disease and its relationship to gray matter atrophy. Radiology 2011, 258(3):853-863.
3. Backman L., Jones S., Berger A.K., et al. Multiple cognitive deficits during the transition to Alzheimer's disease. J. Intern. Med. 2004, 256(3):195-204.
4. Riviere S., Gillette-Guyonnet S., Andrieu S., et al. Cognitive function and caregiver burden: predictive factors for eating behaviour disorders in Alzheimer's disease. Int. J. Geriatr. Psychiatry 2002, 17(10):950-955.
5. Johnson D.K., Wilkins C.H., Morris J.C. Accelerated weight loss may precede diagnosis in Alzheimer disease. Arch. Neurol. 2006, 63(9):1312-1317.
6. Etcheberrigaray R., Ibarreta D. Ionic channels and second messenger alterations in Alzheimer's disease. Relevance of studies in nonneuronal cells. Rev. Neurol. 2001, 33(8):740-749.
7. Bruel A., Cherqui G., Columelli S., et al. Reduced protein kinase C activity in sporadic Alzheimer's disease fibroblasts. Neurosci. Lett. 1991, 133(1):89-92.
8. Swerdlow R.H.K. SJ Mitochondria in Alzheimer's disease. Int. Rev. Neurobiol. 2002, 53:341-385.
9. Leuner K., Schulz K., Schutt T., et al. Peripheral mitochondrial dysfunction in Alzheimer's disease: focus on lymphocytes. Mol. Neurobiol. 2012, 46(1):194-204.
10. Nelson M.E., Rejeski W.J., Blair S.N., et al. Physical activity and public health in older adults: recommendation from the American College of Sports Medicine and the American Heart Association. Med. Sci. Sports Exerc. 2007, 39(8):1435-1445.
11. Scarmeas N., Luchsinger J.A., Schupf N., et al. Physical activity, diet, and risk of Alzheimer disease. JAMA 2009, 302(6):627-637.
12. Neeper S.A., Gomezpinilla F., Choi J., et al. Exercise and brain neurotrophins. Nature 1995, 373(6510):109.
13. Churchill J.D., Galvez R., Colcombe S., et al. Exercise, experience and the aging brain*1. Neurobiol. Aging 2002, 23(5):941-955.
14. van Praag H., Christie B.R., Sejnowski T.J., et al. Running enhances neurogenesis, learning, and long-term potentiation in mice. Proc. Natl. Acad. Sci. U. S. A. 1999, 96(23):13427-13431.
15. Lakka T.A., Laukkanen J.A., Rauramaa R., et al. Cardiorespiratory fitness and the progression of carotid atherosclerosis in middle-aged men. Ann. Intern. Med. 2001, 134(1):12-20.
16. Blair S.N., Kampert J.B., Kohl H.W., et al. Influences of cardiorespiratory fitness and other precursors on cardiovascular disease and all-cause mortality in men and women. JAMA 1996, 276(3):205-210.
17. Kurl S., Laukkanen J.A., Rauramaa R., et al. Cardiorespiratory fitness and the risk for stroke in men. Arch. Intern. Med. 2003, 163(14):1682-1688.
18. Seals D.R., Hagberg J.M., Hurley B.F., et al. Effects of endurance training on glucose tolerance and plasma lipid levels in older men and women. JAMA 1984, 252(5):645-649.
19. Hughes V.A., Fiatarone M.A., Fielding R.A., et al. Exercise increases muscle GLUT-4 levels and insulin action in subjects with impaired glucose tolerance. Am. J. Physiol. 1993, 264(6 Pt 1):E855-E862.
20. Kirwan J.P., Kohrt W.M., Wojta D.M., et al. Endurance exercise training reduces glucose-stimulated insulin levels in 60- to 70-year-old men and women. J. Gerontol. 1993, 48(3):M84-M90.
21. Cox J.H., Cortright R.N., Dohm G.L., et al. Effect of aging on response to exercise training in humans: skeletal muscle GLUT-4 and insulin sensitivity. J. Appl. Physiol. 1999, 86(6):2019-2025.
22. Kahn S.E., Larson V.G., Beard J.C., et al. Effect of exercise on insulin action, glucose tolerance, and insulin secretion in aging. Am. J. Physiol. 1990, 258(6 Pt 1):E937-E943.
23. Houmard J.A., Tyndall G.L., Midyette J.B., et al. Effect of reduced training and training cessation on insulin action and muscle GLUT-4. J. Appl. Physiol. 1996, 81(3):1162-1168.
24. Wyss-Coray T., Rogers J. Inflammation in Alzheimer disease - a brief review of the basic science and clinical literature. Cold Spring Harb. Perspect. Med. 2012, 2(1):a006346.
25. Ford E.S. Does exercise reduce inflammation? Physical activity and C-reactive protein among U.S. adults. Epidemiology 2002, 13(5):561-568.
26. Dustman R.E., Emmerson R.Y., Ruhling R.O., et al. Age and fitness effects on EEG, ERPs, visual sensitivity, and cognition. Neurobiol. Aging 1990, 11(3):193-200.
27. van Boxtel M.P., Paas F.G., Houx P.J., et al. Aerobic capacity and cognitive performance in a cross-sectional aging study. Med. Sci. Sports Exerc. 1997, 29(10):1357-1365.
28. Shay K.A., Roth D.L. Association between aerobic fitness and visuospatial performance in healthy older adults. Psychol. Aging 1992, 7(1):15-24.
29. Hillman C.H., Motl R.W., Pontifex M.B., et al. Physical activity and cognitive function in a cross-section of younger and older community-dwelling individuals. Health Psychol. 2006, 25(6):678-687.
30. Bixby W.R., Spalding T.W., Haufler A.J., et al. The unique relation of physical activity to executive function in older men and women. Med. Sci. Sports Exerc. 2007, 39(8):1408-1416.
31. Laurin D., Verreault R., Lindsay J., et al. Physical activity and risk of cognitive impairment and dementia in elderly persons. Arch. Neurol. 2001, 58(3):498-504.
32. Yaffe K., Barnes D., Nevitt M., et al. A prospective study of physical activity and cognitive decline in elderly women: women who walk. Arch. Intern. Med. 2001, 161(14):1703-1708.
33. Pignatti F., Rozzini R., Trabucchi M., et al. Physical activity and cognitive decline in elderly persons. Arch. Intern. Med. 2002, 162(3):361-362.
34. Albert M.S., Jones K., Savage C.R., et al. Predictors of cognitive change in older persons: MacArthur studies of successful aging. Psychol. Aging 1995, 10(4):578-589.
35. Weuve J., Kang J.H., Manson J.E., et al. Physical activity, including walking, and cognitive function in older women. JAMA 2004, 292(12):1454-1461.
36. Larson E.B., Wang L., Bowen J.D., et al. Exercise is associated with reduced risk for incident dementia among persons 65years of age and older. Ann. Intern. Med. 2006, 144(2):73-81.
37. Friedland R.P., Fritsch T., Smyth K.A., et al. Patients with Alzheimer's disease have reduced activities in midlife compared with healthy control-group members. Proc. Natl. Acad. Sci. 2001, 98(6):3440-3445.
38. Buchman A.S., Boyle P.A., Yu L., et al. Total daily physical activity and the risk of AD and cognitive decline in older adults. Neurology 2012, 78(17):1323-1329.
39. Lautenschlager N.T., Cox K.L., Flicker L., et al. Effect of physical activity on cognitive function in older adults at risk for Alzheimer disease: a randomized trial. JAMA 2008, 300(9):1027-1037.
40. Kramer A.F., Hahn S., Cohen N.J., et al. Ageing, fitness and neurocognitive function. Nature 1999, 400(6743):418-419.
41. Colcombe S., Kramer A.F. Fitness effects on the cognitive function of older adults: a meta-analytic study. Psychol. Sci. 2003, 14(2):125-130.
42. Erickson K.I., Raji C.A., Lopez O.L., et al. Physical activity predicts gray matter volume in late adulthood: the cardiovascular health study. Neurology 2010, 75(16):1415-1422.
43. Liu-Ambrose T., Nagamatsu L.S., Graf P., et al. Resistance training and executive functions: a 12-month randomized controlled trial. Arch. Intern. Med. 2010, 170(2):170-178.
44. Honea R.A., Thomas G.P., Harsha A., et al. Cardiorespiratory fitness and preserved medial temporal lobe volume in Alzheimer disease. Alzheimer Dis. Assoc. Disord. 2009, 23(3):188-197.
45. Burns J.M., Cronk B.B., Anderson H.S., et al. Cardiorespiratory fitness and brain atrophy in early Alzheimer disease. Neurology 2008, 71(3):210-216.
46. Erickson K.I., Voss M.W., Prakash R.S., et al. Exercise training increases size of hippocampus and improves memory. Proc. Natl. Acad. Sci. U. S. A. 2011, 108(7):3017-3022.
47. Huang A.M., Jen C.J., Chen H.F., et al. Compulsive exercise acutely upregulates rat hippocampal brain-derived neurotrophic factor. J. Neural Transm. 2006, 113(7):803-811.
48. Vaynman S., Ying Z., Gomez-Pinilla F. Hippocampal BDNF mediates the efficacy of exercise on synaptic plasticity and cognition. Eur. J. Neurosci. 2004, 20(10):2580-2590.
49. Nagamatsu L.S., Handy T.C., Hsu C.L., et al. Resistance training promotes cognitive and functional brain plasticity in seniors with probable mild cognitive impairment. Arch. Intern. Med. 2012, 172(8):666-668.
50. Buchman A.S., Wilson R.S., Boyle P.A., et al. Grip strength and the risk of incident Alzheimer's disease. Neuroepidemiology 2007, 29(1-2):66-73.
51. Boyle P.A., Buchman A.S., Wilson R.S., et al. Association of muscle strength with the risk of Alzheimer disease and the rate of cognitive decline in community-dwelling older persons. Arch. Neurol. 2009, 66(11):1339-1344.
52. Burns J.M., Johnson D.K., Watts A., et al. Reduced lean mass in early Alzheimer disease and its association with brain atrophy. Arch. Neurol. 2010, 67(4):428-433.
53. Loskutova N., Honea R.A., Vidoni E.D., et al. Bone density and brain atrophy in early Alzheimer's disease. J. Alzheimers Dis. 2009, 18(4):777-785.
54. Loskutova N., Honea R.A., Brooks W.M., et al. Reduced limbic and hypothalamic volumes correlate with bone density in early Alzheimer's disease. J. Alzheimers Dis. 2010, 20(1):313-322.
55. Janson J., Laedtke T., Parisi J.E., et al. Increased risk of type 2 diabetes in Alzheimer disease. Diabetes 2004, 53(2):474-481.
56. Arvanitakis Z., Wilson R.S., Bienias J.L., et al. Diabetes mellitus and risk of Alzheimer disease and decline in cognitive function. Arch. Neurol. 2004, 61(5):661-666.
57. Luchsinger J.A., Reitz C., Patel B., et al. Relation of diabetes to mild cognitive impairment. Arch. Neurol. 2007, 64(4):570-575.
58. Ott A., Stolk R.P., van Harskamp F., et al. Diabetes mellitus and the risk of dementia: the Rotterdam Study. Neurology 1999, 53(9):1937-1942.
59. Peila R., Rodriguez B.L., Launer L.J. Type 2 diabetes, APOE gene, and the risk for dementia and related pathologies: the Honolulu-Asia Aging Study. Diabetes 2002, 51(4):1256-1262.
60. Xu W., Qiu C., Gatz M., et al. Mid- and late-life diabetes in relation to the risk of dementia: a population-based twin study. Diabetes 2009, 58(1):71-77.
61. Velayudhan L., Poppe M., Archer N., et al. Risk of developing dementia in people with diabetes and mild cognitive impairment. Br. J. Psychiatry 2010, 196(1):36-40.
62. Morris J.K., Vidoni E.D., Honea R.A., et al. Impaired glycemia increases disease progression in mild cognitive impairment. Neurobiol. Aging 2014, 35(3):585-589.
63. Mosconi L. Brain glucose metabolism in the early and specific diagnosis of Alzheimer's disease. FDG-PET studies in MCI and AD. Eur. J. Nucl. Med. Mol. Imaging 2005, 32(4):486-510.
64. Mosconi L., Tsui W.H., De Santi S., et al. Reduced hippocampal metabolism in MCI and AD: automated FDG-PET image analysis. Neurology 2005, 64(11):1860-1867.
65. Banks W.A. The source of cerebral insulin. Eur. J. Pharmacol. 2004, 490(1-3):5-12.
66. Skeberdis V.A., Lan J., Zheng X., et al. Insulin promotes rapid delivery of N-methyl-D-aspartate receptors to the cell surface by exocytosis. Proc. Natl. Acad. Sci. U. S. A. 2001, 98(6):3561-3566.
67. Jin Z., Jin Y., Kumar-Mendu S., et al. Insulin reduces neuronal excitability by turning on GABA(A) channels that generate tonic current. PLoS One 2011, 6(1):e16188.
68. Wan Q., Xiong Z.G., Man H.Y., et al. Recruitment of functional GABA(A) receptors to postsynaptic domains by insulin. Nature 1997, 388(6643):686-690.
69. van der Heide L.P., Ramakers G.M.J., Smidt M.P. Insulin signaling in the central nervous system: learning to survive. Prog. Neurobiol. 2006, 79(4):205-221.
70. Gasparini L., Gouras G.K., Wang R., et al. Stimulation of beta-amyloid precursor protein trafficking by insulin reduces intraneuronal beta-amyloid and requires mitogen-activated protein kinase signaling. J. Neurosci. 2001, 21(8):2561-2570.
71. Steen E., Terry B.M., Rivera E.J., et al. Impaired insulin and insulin-like growth factor expression and signaling mechanisms in Alzheimer's disease - is this type 3 diabetes?. J. Alzheimers Dis. 2005, 7(1):63-80.
72. Talbot K., Wang H.Y., Kazi H., et al. Demonstrated brain insulin resistance in Alzheimer's disease patients is associated with IGF-1 resistance, IRS-1 dysregulation, and cognitive decline. J. Clin. Invest. 2012, 63(4):1316-1338.
73. Luchsinger J.A., Tang M.X., Shea S., et al. Hyperinsulinemia and risk of Alzheimer disease. Neurology 2004, 63(7):1187-1192.
74. Burns J.M., Donnelly J.E., Anderson H.S., et al. Peripheral insulin and brain structure in early Alzheimer disease. Neurology 2007, 69(11):1094-1104.
75. Burns J.M., Honea R.A., Vidoni E.D., et al. Insulin is differentially related to cognitive decline and atrophy in Alzheimer's disease and aging. Biochim. Biophys. Acta 2012, 1822(3):333-339.
76. Greenwood C.E., Kaplan R.J., Hebblethwaite S., et al. Carbohydrate-induced memory impairment in adults with type 2 diabetes. Diabetes Care 2003, 26(7):1961-1966.
77. Ravona-Springer R., Moshier E., Schmeidler J., et al. Changes in glycemic control are associated with changes in cognition in non-diabetic elderly. J. Alzheimers Dis. 2012, 30(2):299-309.
78. Vanhanen M., Koivisto K., Kuusisto J., et al. Cognitive function in an elderly population with persistent impaired glucose tolerance. Diabetes Care 1998, 21(3):398-402.
79. Benedict C., Brooks S.J., Kullberg J., et al. Impaired insulin sensitivity as indexed by the HOMA score is associated with deficits in verbal fluency and temporal lobe gray matter volume in the elderly. Diabetes Care 2012, 35(3):488-494.
80. Xie L., Helmerhorst E., Taddei K., et al. Alzheimer's beta-amyloid peptides compete for insulin binding to the insulin receptor. J. Neurosci. 2002, 22(10):RC221.
81. Farris W., Mansourian S., Chang Y., et al. Insulin-degrading enzyme regulates the levels of insulin, amyloid á-protein, and the á-amyloid precursor protein intracellular domain in vivo. PNAS 2003, 100(7):4162-4167.
82. Thambisetty M., Metter E.J., Yang A., et al. Glucose intolerance, insulin resistance, and pathological features of Alzheimer disease in the Baltimore longitudinal study of aging. JAMA Neurol. 2013, 70(9):1167-1172.
83. Jackson K., Barisone G.A., Diaz E., et al. Amylin deposition in the brain: a second amyloid in Alzheimer disease?. Ann. Neurol. 2013, 74(4):517-526.
84. Kimura R., MacTavish D., Yang J., et al. Beta amyloid-induced depression of hippocampal long-term potentiation is mediated through the amylin receptor. J. Neurosci. 2012, 32(48):17401-17406.
85. Fitzpatrick A.L., Kuller L.H., Lopez O.L., et al. Midlife and late-life obesity and the risk of dementia: cardiovascular health study. Arch. Neurol. 2009, 66(3):336-342.
86. Tolppanen A.M., Ngandu T., Kareholt I., et al. Midlife and late-life body mass index and late-life dementia: results from a prospective population-based cohort. J. Alzheimers Dis. 2014, 38(1):201-209.
87. Profenno L.A., Porsteinsson A.P., Faraone S.V. Meta-analysis of Alzheimer's disease risk with obesity, diabetes, and related disorders. Biol. Psychiatry 2010, 67(6):505-512.
88. Gazdzinski S., Kornak J., Weiner M.W., et al. Body mass index and magnetic resonance markers of brain integrity in adults. Ann. Neurol. 2008, 63(5):652-657.
89. Gustafson D., Lissner L., Bengtsson C., et al. A 24-year follow-up of body mass index and cerebral atrophy. Neurology 2004, 63(10):1876-1881.
90. Whitmer R.A., Gunderson E.P., Barrett-Connor E., et al. Obesity in middle age and future risk of dementia: a 27year longitudinal population based study. BMJ 2005, 330(7504):1360.
91. Gustafson D., Rothenberg E., Blennow K., et al. An 18-year follow-up of overweight and risk of Alzheimer disease. Arch. Intern. Med. 2003, 163(13):1524-1528.
92. Despres J.P. Dyslipidaemia and obesity. Baillieres Clin. Endocrinol. Metab. 1994, 8(3):629-660.
93. Dias H.K.I., Mistry J., Tarzyluck M., Hill E.J., Bennett S.J., Polidori M.C., Lip G.Y.H., Griffiths H.R. Oxidised LDL-lipids alter redox ratio, lipid raft formation and increase amyloid beta production by SHSY-5Y cells. Exp. Gerontol. 2013, 48(7):688.
94. Grandl M., Bared S.M., Liebisch G., et al. E-LDL and Ox-LDL differentially regulate ceramide and cholesterol raft microdomains in human macrophages. Cytometry A 2006, 69(3):189-191.
95. Ehehalt R., Keller P., Haass C., et al. Amyloidogenic processing of the Alzheimer beta-amyloid precursor protein depends on lipid rafts. J. Cell Biol. 2003, 160(1):113-123.
96. Bhattacharyya R., Barren C., Kovacs D.M. Palmitoylation of amyloid precursor protein regulates amyloidogenic processing in lipid rafts. J. Neurosci. 2013, 33(27):11169-11183.
97. Han X., Rozen S., Boyle S.H., et al. Metabolomics in early Alzheimer's disease: identification of altered plasma sphingolipidome using shotgun lipidomics. PLoS One 2011, 6(7):e21643.
98. Mielke M.M., Bandaru V.V., Haughey N.J., et al. Serum ceramides increase the risk of Alzheimer disease: the Women's Health and Aging Study II. Neurology 2012, 79(7):633-641.
99. Mielke M.M., Haughey N.J., Ratnam Bandaru V.V., et al. Plasma ceramides are altered in mild cognitive impairment and predict cognitive decline and hippocampal volume loss. Alzheimers Dement. 2010, 6(5):378-385.
100. Puglielli L., Ellis B.C., Saunders A.J., et al. Ceramide stabilizes beta-site amyloid precursor protein-cleaving enzyme 1 and promotes amyloid beta-peptide biogenesis. J. Biol. Chem. 2003, 278(22):19777-19783.
101. Morita S.Y., Nakano M., Sakurai A., et al. Formation of ceramide-enriched domains in lipid particles enhances the binding of apolipoprotein E. FEBS Lett. 2005, 579(7):1759-1764.
102. Lucic D., Huang Z.H., Gu D., et al. Cellular sphingolipids regulate macrophage apolipoprotein E secretion. Biochemistry 2007, 46(39):11196-11204.
103. Kilkus J., Goswami R., Testai F.D., et al. Ceramide in rafts (detergent-insoluble fraction) mediates cell death in neurotumor cell lines. J. Neurosci. Res. 2003, 72(1):65-75.
104. Luberto C., Hassler D.F., Signorelli P., et al. Inhibition of tumor necrosis factor-induced cell death in MCF7 by a novel inhibitor of neutral sphingomyelinase. J. Biol. Chem. 2002, 277(43):41128-41139.
105. Schmitz-Peiffer C. Targeting ceramide synthesis to reverse insulin resistance. Diabetes 2010, 59(10):2351-2353.
106. Cronk B.B., Johnson D.K., Burns J.M. Body mass index and cognitive decline in mild cognitive impairment. Alzheimer Dis. Assoc. Disord. 2010, 24(2):126-130.
107. Atti A.R., Palmer K., Volpato S., et al. Late-life body mass index and dementia incidence: nine-year follow-up data from the Kungsholmen Project. J. Am. Geriatr. Soc. 2008, 56(1):111-116.
108. Nourhashemi F., Deschamps V., Larrieu S., et al. Body mass index and incidence of dementia: the PAQUID study. Neurology 2003, 60(1):117-119.
109. Akiyama H., Barger S., Barnum S., et al. Inflammation and Alzheimer's disease. Neurobiol. Aging 2000, 21(3):383-421.
110. Holmes C., Cunningham C., Zotova E., et al. Systemic inflammation and disease progression in Alzheimer disease. Neurology 2009, 73(10):768-774.
111. Tan Z.S., Beiser A.S., Vasan R.S., et al. Inflammatory markers and the risk of Alzheimer disease: the Framingham Study. Neurology 2007, 68(22):1902-1908.
112. Zinman B., Hanley A.J., Harris S.B., et al. Circulating tumor necrosis factor-alpha concentrations in a native Canadian population with high rates of type 2 diabetes mellitus. J. Clin. Endocrinol. Metab. 1999, 84(1):272-278.
113. Hu W.T., Holtzman D.M., Fagan A.M., et al. Plasma multianalyte profiling in mild cognitive impairment and Alzheimer disease. Neurology 2012, 79(9):897-905.
114. Cote S., Carmichael P.H., Verreault R., et al. Nonsteroidal anti-inflammatory drug use and the risk of cognitive impairment and Alzheimer's disease. Alzheimers Dement. 2012, 8(3):219-226.
115. Andersen K., Launer L.J., Ott A., et al. Do nonsteroidal anti-inflammatory drugs decrease the risk for Alzheimer's disease?. Neurology 1995, 45:1441-1445.
116. in t' Veld B.A., Ruitenberg A., Hofman A., et al. Nonsteroidal antiinflammatory drugs and the risk of Alzheimer's disease. N. Engl. J. Med. 2001, 345(21):1515-1521.
117. Lyketsos C.G., Breitner J.C., Green R.C., et al. Naproxen and celecoxib do not prevent AD in early results from a randomized controlled trial. Neurology 2007, 68(21):1800-1808.
118. Aisen P.S., Schafer K., Grundman M., et al. Results of a multicenter trial of rofecoxib and naproxen in Alzheimer's disease. Neurobiol. Aging 2003, 23(1S):s429.
119. Martin B.K., Szekely C., Brandt J., et al. Cognitive function over time in the Alzheimer's Disease Anti-inflammatory Prevention Trial (ADAPT): results of a randomized, controlled trial of naproxen and celecoxib. Arch. Neurol. 2008, 65(7):896-905.
120. Meinert C.L., McCaffrey L.D., Breitner J.C. Alzheimer's disease anti-inflammatory prevention trial: design, methods, and baseline results. Alzheimers Dement. 2009, 5(2):93-104.
121. Zaidi M. Skeletal remodeling in health and disease. Nat. Med. 2007, 13(7):791-801.
122. Barrett-Connor E., Edelstein S.L., Corey-Bloom J., et al. Weight loss precedes dementia in community-dwelling older adults. J. Am. Geriatr. Soc. 1996, 44(10):1147-1152.
123. Buchman A.S., Wilson R.S., Bienias J.L., et al. Change in body mass index and risk of incident Alzheimer disease. Neurology 2005, 65(6):892-897.
124. Stewart R., Masaki K., Xue Q.L., et al. A 32-year prospective study of change in body weight and incident dementia: the Honolulu-Asia Aging Study. Arch. Neurol. 2005, 62(1):55-60.
125. BarrettConnor E., Edelstein S.L., CoreyBloom J., et al. Weight loss precedes dementia in community-dwelling older adults. J. Am. Geriatr. Soc. 1996, 44(10):1147-1152.
126. White H., Pieper C., Schmader K., et al. Weight change in Alzheimer's disease. J. Am. Geriatr. Soc. 1996, 44(3):265-272.
127. Knopman D.S., Edland S.D., Cha R.H., et al. Incident Dementia in Women is Preceded by Weight Loss by At Least a Decade 2007, 739-746.
128. Vidoni E.D., Townley R.A., Honea R.A., et al. Alzheimer disease biomarkers are associated with body mass index. Neurology 2011, 77(21):1913-1920.
129. Buchman A.S., Schneider J.A., Wilson R.S., et al. Body mass index in older persons is associated with Alzheimer disease pathology. Neurology 2006, 67(11):1949-1954.
130. Goldman W.P., Baty J.D., Buckles V.D., et al. Motor dysfunction in mildly demented AD individuals without extrapyramidal signs. Neurology 1999, 53(5):956.
131. Auyeung T.W., Kwok T., Lee J., et al. Functional decline in cognitive impairment - the relationship between physical and cognitive function. Neuroepidemiology 2008, 31(3):167-173.
132. Rogers S.D., Jarrot S.E. Cognitive impairment and effects on upper body strength of adults with dementia. J. Aging Phys. Act. 2008, 16(1):61-68.
133. Vidoni E.D., Honea R.A., Billinger S.A., et al. Cardiorespiratory fitness is associated with atrophy in Alzheimer's and aging over 2years. Neurobiol. Aging 2012, 33(8):1624-1632.
134. Mahley R.W., Rall S.C. Apolipoprotein E: far more than a lipid transport protein. Annu. Rev. Genomics Hum. Genet. 2000, 1:507-537.
135. Dean D.C., Jerskey B.A., Chen K., et al. Brain differences in infants at differential genetic risk for late-onset Alzheimer disease: a cross-sectional imaging study. JAMA Neurol. 2013, 71(1):11-22.
136. Honea R.A., Vidoni E., Harsha A., et al. Impact of APOE on the healthy aging brain: a voxel-based MRI and DTI study. J. Alzheimers Dis. 2009, 18(3):553-564.
137. Reiman E.M. Linking brain imaging and genomics in the study of Alzheimer's disease and aging. Ann. N. Y. Acad. Sci. 2007, 1097:94-113.
138. Schilling S., DeStefano A.L., Sachdev P.S., et al. APOE genotype and MRI markers of cerebrovascular disease: systematic review and meta-analysis. Neurology 2013, 81(3):292-300.
139. Villain N., Desgranges B., Viader F., et al. Relationships between hippocampal atrophy, white matter disruption, and gray matter hypometabolism in Alzheimer's disease. J. Neurosci. 2008, 28(24):6174-6181.
140. Reiman E.M., Caselli R.J., Yun L.S., et al. Preclinical evidence of Alzheimer's disease in persons homozygous for the {epsilon}4 allele for apolipoprotein E. N. Engl. J. Med. 1996, 334(12):752-758.
141. Reiman E.M., Caselli R.J., Chen K., et al. Declining brain activity in cognitively normal apolipoprotein E epsilon 4 heterozygotes: a foundation for using positron emission tomography to efficiently test treatments to prevent Alzheimer's disease. Proc. Natl. Acad. Sci. U. S. A. 2001, 98(6):3334-3339.
142. Reiman E.M., Chen K., Alexander G.E., et al. Correlations between apolipoprotein E epsilon4 gene dose and brain-imaging measurements of regional hypometabolism. Proc. Natl. Acad. Sci. U. S. A. 2005, 102(23):8299-8302.
143. Dennis N.A., Browndyke J.N., Stokes J., et al. Temporal lobe functional activity and connectivity in young adult APOE varepsilon4 carriers. Alzheimers Dement. 2010, 6(4):303-311.
144. Filbey F.M., Slack K.J., Sunderland T.P., et al. Functional magnetic resonance imaging and magnetoencephalography differences associated with APOEepsilon4 in young healthy adults. Neuroreport 2006, 17(15):1585-1590.
145. Filippini N., MacIntosh B.J., Hough M.G., et al. Distinct patterns of brain activity in young carriers of the APOE-epsilon4 allele. Proc. Natl. Acad. Sci. U. S. A. 2009, 106(17):7209-7214.
146. Raichle M.E., MacLeod A.M., Snyder A.Z., et al. A default mode of brain function. Proc. Natl. Acad. Sci. U. S. A. 2001, 98(2):676-682.
147. Buckner R.L., Snyder A.Z., Shannon B.J., et al. Molecular, structural, and functional characterization of Alzheimer's disease: evidence for a relationship between default activity, amyloid, and memory. J. Neurosci. 2005, 25(34):7709-7717.
148. Valla J., Yaari R., Wolf A.B., et al. Reduced posterior cingulate mitochondrial activity in expired young adult carriers of the APOE epsilon4 allele, the major late-onset Alzheimer's susceptibility gene. J. Alzheimers Dis. 2010, 22(1):307-313.
149. Rovio S., Kareholt I., Helkala E.L., et al. Leisure-time physical activity at midlife and the risk of dementia and Alzheimer's disease. Lancet Neurol. 2005, 4(11):705-711.
150. Morris J.K., Vidoni E.D., Honea R.A., Burns J.M. Impaired glycemia increases disease progression in mild cognitive impairment. Neurobiol. Aging 2013, 35(3):585-589.
151. Ragogna F., Lattuada G., Ruotolo G., et al. Lack of association of apoE epsilon4 allele with insulin resistance. Acta Diabetol. 2012, 49(1):25-32.
152. Lambert J.C., Amouyel P. Genetics of Alzheimer's disease: new evidences for an old hypothesis?. Curr. Opin. Genet. Dev. 2011, 21(3):295-301.
153. Li H., Wetten S., Li L., et al. Candidate single-nucleotide polymorphisms from a genomewide association study of Alzheimer disease. Arch. Neurol. 2008, 65(1):45-53.
154. Reiman E.M., Webster J.A., Myers A.J., et al. GAB2 alleles modify Alzheimer's risk in APOE epsilon4 carriers. Neuron 2007, 54(5):713-720.
155. Carrasquillo M.M., Zou F., Pankratz V.S., et al. Genetic variation in PCDH11X is associated with susceptibility to late-onset Alzheimer's disease. Nat. Genet. 2009, 41(2):192-198.
156. Alperovitch A., Boland A., Delepoine M., et al. Meta-analysis of 74,046 individuals identifies 11 new susceptibility loci for Alzheimer's disease. Nat. Genet. 2013, 45(12):1452-1458.
157. Harold D., Abraham R., Hollingworth P., et al. Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer's disease. Nat. Genet. 2009, 41(10):1088-1093.
158. Lambert J.C., Heath S., Even G., et al. Genome-wide association study identifies variants at CLU and CR1 associated with Alzheimer's disease. Nat. Genet. 2009, 41(10):1094-1099.
159. Carrasquillo M.M., Belbin O., Hunter T.A., et al. Replication of CLU, CR1, and PICALM associations with Alzheimer disease. Arch. Neurol. 2010, 67(8):961-964.
160. Jun G., Naj A.C., Beecham G.W., et al. Meta-analysis confirms CR1, CLU, and PICALM as Alzheimer disease risk loci and reveals interactions with APOE genotypes. Arch. Neurol. 2010, 67(12):1473-1484.
161. Hollingworth P., Harold D., Sims R., et al. Common variants at ABCA7, MS4A6A/MS4A4E, EPHA1, CD33 and CD2AP are associated with Alzheimer's disease. Nat. Genet. 2011, 43(5):429-435.
162. Naj A.C., Jun G., Beecham G.W., et al. Common variants at MS4A4/MS4A6E, CD2AP, CD33 and EPHA1 are associated with late-onset Alzheimer's disease. Nat. Genet. 2011, 43(5):436-441.
163. Hu X., Pickering E., Liu Y.C., et al. Meta-analysis for genome-wide association study identifies multiple variants at the BIN1 locus associated with late-onset Alzheimer's disease. PLoS One 2011, 6(2):e16616.
164. Seshadri S., Fitzpatrick A.L., Ikram M.A., et al. Genome-wide analysis of genetic loci associated with Alzheimer disease. JAMA 2010, 303(18):1832-1840.
165. Gandhi S., Wood N.W. Genome-wide association studies: the key to unlocking neurodegeneration?. Nat. Neurosci. 2010, 13(7):789-794.
166. Swerdlow R.H., Burns J.M., Khan S.M. The Alzheimer's disease mitochondrial cascade hypothesis. J. Alzheimers Dis. 2010, 20(Suppl. 2):S265-S279.
167. Pathak D., Berthet A., Nakamura K. Energy failure: does it contribute to neurodegeneration?. Ann. Neurol. 2013, 74(4):506-516.
168. Parker W.D., Filley C.M., Parks J.K. Cytochrome oxidase deficiency in Alzheimer's disease. Neurology 1990, 40(8):1302-1303.
169. Martins A.R., Nachbar R.T., Gorjao R., et al. Mechanisms underlying skeletal muscle insulin resistance induced by fatty acids: importance of the mitochondrial function. Lipids Health Dis. 2012, 11:30.
170. Gupte A.A., Bomhoff G.L., Swerdlow R.H., et al. Heat treatment improves glucose tolerance and prevents skeletal muscle insulin resistance in rats fed a high-fat diet. Diabetes 2009, 58(3):567-578.
171. Supale S., Thorel F., Merkwirth C., et al. Loss of prohibitin induces mitochondrial damages altering beta-cell function and survival and is responsible for gradual diabetes development. Diabetes 2013, 62(10):3488-3499.
172. Thyfault J.P., Cree M.G., Zheng D., et al. Contraction of insulin-resistant muscle normalizes insulin action in association with increased mitochondrial activity and fatty acid catabolism. Am. J. Physiol. Cell Physiol. 2007, 292(2):C729-C739.
173. Ridge P.G., Koop A., Maxwell T.J., et al. Mitochondrial haplotypes associated with biomarkers for Alzheimer's disease. PLoS One 2013, 8(9):e74158.
174. Honea R.A., Swerdlow R.H., Vidoni E.D., et al. Progressive regional atrophy in normal adults with a maternal history of Alzheimer disease. Neurology 2011, 76(9):822-829.
175. Mosconi L., Brys M., Switalski R., et al. Maternal family history of Alzheimer's disease predisposes to reduced brain glucose metabolism. Proc. Natl. Acad. Sci. U. S. A. 2007, 104(48):19067-19072.
176. Honea R.A., Vidoni E.D., Swerdlow R.H., et al. Maternal family history is associated with Alzheimer's disease biomarkers. J. Alzheimers Dis. 2012, 31(3):659-668.
177. Swerdlow R.H., Burns J.M., Khan S.M. The Alzheimer's disease mitochondrial cascade hypothesis: progress and perspectives. Biochim. Biophys. Acta 2013.
178. Navarro A., Boveris A. The mitochondrial energy transduction system and the aging process. Am. J. Physiol. Cell Physiol. 2007, 292(2):C670-C686.
179. Barrientos A., Casademont J., Cardellach F., et al. Reduced steady-state levels of mitochondrial RNA and increased mitochondrial DNA amount in human brain with aging. Brain Res. Mol. Brain Res. 1997, 52(2):284-289.
180. Kish S.J., Bergeron C., Rajput A., et al. Brain cytochrome oxidase in Alzheimer's disease. J. Neurochem. 1992, 59(2):776-779.
181. Mutisya E.M., Bowling A.C., Beal M.F. Cortical cytochrome oxidase activity is reduced in Alzheimer's disease. J. Neurochem. 1994, 63(6):2179-2184.
182. Maurer I., Zierz S., Moller H.J. A selective defect of cytochrome c oxidase is present in brain of Alzheimer disease patients. Neurobiol. Aging 2000, 21(3):455-462.
183. Long J., He P., Shen Y., et al. New evidence of mitochondria dysfunction in the female Alzheimer's disease brain: deficiency of estrogen receptor-beta. J. Alzheimers Dis. 2012, 30(3):545-558.
184. Valla J., Berndt J.D., Gonzalez-Lima F. Energy hypometabolism in posterior cingulate cortex of Alzheimer's patients: superficial laminar cytochrome oxidase associated with disease duration. J. Neurosci. 2001, 21(13):4923-4930.
185. Mosconi L., de Leon M., Murray J., et al. Reduced mitochondria cytochrome oxidase activity in adult children of mothers with Alzheimer's disease. J. Alzheimers Dis. 2011, 27(3):483-490.
186. Hamblet N.S., Castora F.J. Elevated levels of the Kearns-Sayre syndrome mitochondrial DNA deletion in temporal cortex of Alzheimer's patients. Mutat. Res. 1997, 379(2):253-262.
187. de la Monte S.M., Luong T., Neely T.R., et al. Mitochondrial DNA damage as a mechanism of cell loss in Alzheimer's disease. Lab. Investig. 2000, 80(8):1323-1335.
188. Coskun P.E., Beal M.F., Wallace D.C. Alzheimer's brains harbor somatic mtDNA control-region mutations that suppress mitochondrial transcription and replication. Proc. Natl. Acad. Sci. U. S. A. 2004, 101(29):10726-10731.
189. Hayashi T., Rizzuto R., Hajnoczky G., et al. MAM: more than just a housekeeper. Trends Cell Biol. 2009, 19(2):81-88.
190. Schon E.A., Area-Gomez E. Mitochondria-associated ER membranes in Alzheimer disease. Mol. Cell. Neurosci. 2013, 55:26-36.
191. Shiao Y.J., Lupo G., Vance J.E. Evidence that phosphatidylserine is imported into mitochondria via a mitochondria-associated membrane and that the majority of mitochondrial phosphatidylethanolamine is derived from decarboxylation of phosphatidylserine. J. Biol. Chem. 1995, 270(19):11190-11198.
192. Pinton P., Giorgi C., Siviero R., et al. Calcium and apoptosis: ER-mitochondria Ca2+ transfer in the control of apoptosis. Oncogene 2008, 27(50):6407-6418.
193. Csordas G., Renken C., Varnai P., et al. Structural and functional features and significance of the physical linkage between ER and mitochondria. J. Cell Biol. 2006, 174(7):915-921.
194. Area-Gomez E., Del Carmen Lara Castillo M., Tambini M.D., et al. Upregulated function of mitochondria-associated ER membranes in Alzheimer disease. EMBO J. 2012, 31(21):4106-4123.
195. Rocha M., Hernandez-Mijares A., Garcia-Malpartida K., et al. Mitochondria-targeted antioxidant peptides. Curr. Pharm. Des. 2010, 16(28):3124-3131.
196. Turrens J.F. Mitochondrial formation of reactive oxygen species. J. Physiol. 2003, 552(Pt 2):335-344.
197. Palmer H.J., Paulson K.E. Reactive oxygen species and antioxidants in signal transduction and gene expression. Nutr. Rev. 1997, 55(10):353-361.
198. Bruce-Keller A.J., Gupta S., Parrino T.E., et al. NOX activity is increased in mild cognitive impairment. Antioxid. Redox Signal. 2010, 12(12):1371-1382.
199. Leuner K., Schutt T., Kurz C., et al. Mitochondrion-derived reactive oxygen species lead to enhanced amyloid beta formation. Antioxid. Redox Signal. 2012, 16(2):1421-1433.
200. Recuero M., Munoz T., Aldudo J., et al. A free radical-generating system regulates APP metabolism/processing. FEBS Lett. 2010, 584(22):4611-4618.
201. Wirths O., Multhaup G., Czech C., et al. Intraneuronal Abeta accumulation precedes plaque formation in beta-amyloid precursor protein and presenilin-1 double-transgenic mice. Neurosci. Lett. 2001, 306(1-2):116-120.
202. Caspersen C., Wang N., Yao J., et al. Mitochondrial Abeta: a potential focal point for neuronal metabolic dysfunction in Alzheimer's disease. FASEB J. 2005, 19(14):2040-2041.
203. Cardoso S.M., Santos S., Swerdlow R.H., et al. Functional mitochondria are required for amyloid beta-mediated neurotoxicity. FASEB J. 2001, 15(8):1439-1441.
204. Yao J., Irwin R.W., Zhao L., et al. Mitochondrial bioenergetic deficit precedes Alzheimer's pathology in female mouse model of Alzheimer's disease. Proc. Natl. Acad. Sci. U. S. A. 2009, 106(34):14670-14675.
205. Pagani L., Eckert A. Amyloid-beta interaction with mitochondria. Int. J. Alzheimers Dis. 2011, 2011:925050.
206. Rhein V., Song X., Wiesner A., et al. Amyloid-beta and tau synergistically impair the oxidative phosphorylation system in triple transgenic Alzheimer's disease mice. Proc. Natl. Acad. Sci. U. S. A. 2009, 106(47):20057-20062.
207. Hansson Petersen C.A., Alikhani N., Behbahani H., et al. The amyloid beta-peptide is imported into mitochondria via the TOM import machinery and localized to mitochondrial cristae. Proc. Natl. Acad. Sci. U. S. A. 2008, 105(35):13145-13150.
208. Humphries A.D., Streimann I.C., Stojanovski D., et al. Dissection of the mitochondrial import and assembly pathway for human Tom40. J. Biol. Chem. 2005, 280(12):11535-11543.
209. Yu C.E., Seltman H., Peskind E.R., et al. Comprehensive analysis of APOE and selected proximate markers for late-onset Alzheimer's disease: patterns of linkage disequilibrium and disease/marker association. Genomics 2007, 89(6):655-665.
210. DeFronzo R.A., Ferrannini E. Insulin resistance. A multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia, and atherosclerotic cardiovascular disease. Diabetes Care 1991, 14(3):173-194.
211. Esposito K., Pontillo A., Di Palo C., et al. Effect of weight loss and lifestyle changes on vascular inflammatory markers in obese women: a randomized trial. JAMA 2003, 289(14):1799-1804.
212. Langa K.M., Foster N.L., Larson E.B. Mixed dementia: emerging concepts and therapeutic implications. JAMA 2004, 292(23):2901-2908.
213. Mirra S.S., Heyman A., McKeel D., et al. The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). Part II. Standardization of the neuropathologic assessment of Alzheimer's disease. Neurology 1991, 41(4):479-486.
214. Snowdon D.A., Greiner L.H., Mortimer J.A., et al. Brain infarction and the clinical expression of Alzheimer disease. J. Am. Med. Assoc. 1997, 277:813-817.
215. Burns J.M., Church J.A., Johnson D.K., et al. White matter lesions are prevalent but differentially related with cognition in aging and early Alzheimer disease. Arch. Neurol. 2005, 62(12):1870-1876.
216. Ahtiluoto S., Polvikoski T., Peltonen M., et al. Diabetes, Alzheimer disease, and vascular dementia. Neurology 2010, 75(13):1195-1202.
217. Viswanathan A., Rocca W.A., Tzourio C. Vascular risk factors and dementia: how to move forward?. Neurology 2009, 72(4):368-374.
218. Breteler M.M.B., Van Swieten J.C., Bots M.L., et al. Cerebral white matter lesions, vascular risk factors, and cognitive function in a population-based study: the Rotterdam study. Neurology 1994, 44:1246-1252.
219. Skoog I., Lernfelt B., Landahl S., et al. 15-year longitudinal study of blood pressure and dementia. Lancet 1996, 347(9009):1141-1145.
220. Kivipelto M., Helkala E.L., Laakso M.P., et al. Midlife vascular risk factors and Alzheimer's disease in later life: longitudinal, population based study. BMJ 2001, 322(7300):1447-1451.
221. Lorenzo A., Razzaboni B., Weir G.C., et al. Pancreatic islet cell toxicity of amylin associated with type-2 diabetes mellitus. Nature 1994, 368(6473):756-760.
222. Schuff N., Matsumoto S., Kmiecik J., et al. Cerebral blood flow in ischemic vascular dementia and Alzheimer's disease, measured by arterial spin-labeling magnetic resonance imaging. Alzheimers Dement. 2009, 5(6):454-462.
223. Peng C., Ma J., Gao X., et al. High glucose induced oxidative stress and apoptosis in cardiac microvascular endothelial cells are regulated by FoxO3a. PLoS One 2013, 8(11):e79739.
224. Ferber E.C., Peck B., Delpuech O., et al. FOXO3a regulates reactive oxygen metabolism by inhibiting mitochondrial gene expression. Cell Death Differ. 2012, 19(6):968-979.